18 signals · bluesky, newsapi, News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Some stress signals present but below significant thresholds.
Low risk signals — no significant operational or reputational pressure detected.
Auto-generated from public signals — AI summary pending. Based on 3 recent signals.
Guardant Health Shares Continue To Outperform: What Is Driving the Move? thebull.com.au
Guardant Health Shares Continue To Outperform: What Is Driving the Move?
Guardant Health, Inc. Stock 12‑Month Price Target Raised to $156.35, Implies 7% Downside TradingView
Stock 12‑Month Price Target Raised to $156.35, Implies 7% Downside TradingView
Precision oncology through liquid biopsy.
Based on 18 signals across 3 sources · snapshot 8 Jul 2026
Moderate — directional but may shift as more signals arrive.
Based on 18 signals across 3 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
Guardant Health stock surges on colon cancer blood test news. investors have a new number to think about this week. Bernstein SocGen Group raised its price target on the cancer-screening company's stock to $200 a share, up from $175. Bernstein also kept its Outperform rating intact. The new price target came less than …
Bernstein also kept its Outperform rating intact.